RPL18 is a structural component of the cytosolic large ribosomal subunit, where it functions as part of the ribonucleoprotein complex responsible for protein synthesis. Beyond its canonical ribosomal role, RPL18 has context-dependent regulatory functions: it negatively regulates the double-stranded RNA-activated protein kinase PKR by competing with dsRNA for binding to PKR's amino-terminal domain, thereby promoting translation and cell growth 1. RPL18 is overexpressed in colorectal cancer tissue 2, and emerging evidence suggests involvement in diverse disease contexts. In calcified aortic valve tissue, decreased RPL18 expression correlates with osteogenic differentiation and exacerbates valve interstitial cell calcification 3. RPL18 expression is significantly upregulated in blood-brain capillaries of Alzheimer's disease patients, suggesting a cerebrovascular-specific mechanism 4, and dengue virus replication depends on RPL18-NS1 protein interaction for efficient viral translation and genome replication 5. Recent work demonstrates that RPL18's 5' UTR sequence enhances synthetic mRNA therapeutic output in human and mouse cells, particularly in cells with elevated reactive oxygen species, with application to aging and obesity models 6. Several compounds including ataluren and ELX-02 have entered clinical development targeting translation-related pathways relevant to ribosomal protein function.